Alkermes wants to augment its pipeline with M&A or licensing deals in serious mental illnesses and substance abuse. “I think ...

Study of 5 million people of all backgrounds finds variations in hundreds of genes; previous studies were on people of ...

Among the myriad drugmakers laying out their plans for the future at this year’s J.P. Morgan Healthcare Conference, Takeda ...

The narcolepsy treatment market is projected to grow from USD 5,301.6 million in 2024 to USD 8,718.3 million by 2034, at a ...

The largest and most diverse genetic study of depression has identified 300 new genetic risk factors for the condition across ...

Scientists said the British-led study provides more hope than ever before that the condition could be tackled through new ...

The world’s largest genetic study into depression has uncovered life-changing discoveries that will revolutionise treatments ...

At the start of each of the last five years, the share price of Alkermes has increased. It’s the kind of steady trajectory ...

Many of us feel drowsy during the day, but what causes it, and what can we do about it when it becomes a problem? Sleep ...

The FDA has expanded the approval of Lumryz (sodium oxybate) extended-release oral suspension to include treatment of pediatric narcolepsy.

About LUMRYZ™ (sodium oxybate) for extended-release oral suspension LUMRYZ, is an extended-release sodium oxybate medication approved by the FDA on May 1, 2023, as the first and only once-at-bedtime ...

Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, announces today that it has acquired at the end ...